Concert Pharmaceuticals — Merger or Acquisition (April 2017)
17 slides from Concert Pharmaceuticals's merger presentation, Apr 10, 2017
Slide 1: Product Innovation. Patient Benefit. April 2017
Proprietary and Confidential. © 2014 Concert Pharmaceuticals, Inc. All Rights Reserved. Product Innovation. Patient Benefit. April 2017
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve substantial risks and uncertainties. All statements, other than statements of historical facts, contai
Slide 3: Additional Information about the Transaction and Where to Find It
This communication is being made in respect of the proposed asset sale with Vertex. The proposed asset sale and the asset purchase agreement will be submitted to the shareholders of the Company for their consideration and approval. In connection with the proposed asset sale, the Company will file a
Slide 4: Corporate Highlights
Corporate Highlights CTP-656, proprietary next-generation treatment for cystic fibrosis – Recent asset purchase agreement with Vertex Pharmaceuticals realizes significant value for CTP-656 Pro forma cash expected to fund operations into 2021 Multiple efficacy studies in 2017 – CTP-543, proprie
Slide 5: Robust Clinical Pipeline
Robust Clinical Pipeline 5 Phase I Phase 2 Product Candidate Lead Indication(s) Worldwide Rights AVP-786 Deuterated dextromethorphan CTP-730 Deuterated apremilast Inflammatory Diseases JZP-386 Deuterated sodium oxybate CTP-543 Deuterated ruxolitinib Phase 3 CTP-656* Deuterated ivacaftor Multiple Neu
Slide 6: CTP-656: Next Generation Treatment for Cystic Fibrosis
CTP-656: Next Generation Treatment for Cystic Fibrosis Cystic fibrosis is a genetic disease affecting ~75,000 patients worldwide Average life expectancy has doubled in last two decades CTP-656 (deuterated analog of ivacaftor*) is a potentiator which improves CFTR activity – Potential to improv
Slide 7: CTP-656: Asset Purchase Agreement
CTP-656: Asset Purchase Agreement Up to $250 million agreement with Vertex Pharmaceuticals – $160 million upfront payment with $90 million in milestone potential – Vertex to acquire all rights to CTP-656 Vertex is a pioneer in CF with a broad pipeline and the capability to efficiently advance CT
Slide 8: CTP-656: U.S. Phase 2 Trial Ongoing
CTP-656: U.S. Phase 2 Trial Ongoing Phase 2 trial in patients with gating mutations initiated December 2016 – 30-40 patients – 4 week treatment duration – 3 doses of CTP-656 – Placebo and Kalydeco comparators – Key endpoints: sweat chloride and FEV1 Trial continuing as planned Phase 2 topline
Slide 9: CTP-543: Potential First Oral Treatment for Alopecia Areata
CTP-543: Potential First Oral Treatment for Alopecia Areata Target indication: moderate-to-severe alopecia areata – Common autoimmune disorder causing partial or widespread loss of hair on the scalp and/or body CTP-543: deuterated ruxolitinib – Ruxolitinib: potent, selective JAK1/2 inhibitor app
Slide 10: Alopecia Areata: A Devastating and Poorly Treated Autoimmune Disease
Alopecia Areata: A Devastating and Poorly Treated Autoimmune Disease Up to 650,000 patients affected with alopecia areata in the U.S. at any given time* Chronic condition affecting women, men and children of all ages Often leads to psychological consequences, including anxiety and depression
Slide 11: Clinical Evidence for Efficacy of Ruxolitinib in Alopecia Areata
Clinical Evidence for Efficacy of Ruxolitinib in Alopecia Areata 11 Open label pilot study of ruxolitinib in alopecia areata patients – 20 mg BID oral ruxolitinib (approved myelofibrosis dose) 9/12 patients (75%) achieved 50%+ regrowth by end of treatment (3-6 months) – Responders averaged 92% r
Slide 12: CTP-543: Phase 1 Program Complete
CTP-543: Phase 1 Program Complete Phase 1 profile supports advancement into Phase 2 Increased exposure with increasing doses Well-tolerated with no serious adverse events reported No new metabolites were observed Interferon g-mediated STAT1 phosphorylation was significantly inhibited at al
Slide 13: CTP-543: Potential First FDA-Approved Oral Treatment for Alopecia Areata
CTP-543: Potential First FDA-Approved Oral Treatment for Alopecia Areata Phase 2a trial planned – Double-blind, placebo-controlled, dose-ranging – Approximately 100 adults with moderate-to- severe alopecia areata At least 50% hair loss as measured by Severity of Alopecia Tool (SALT) – 12 month d
Slide 14: AVP-786: Potential First-in-Class Treatment for Agitation in Alzheimer's Disease
AVP-786: Potential First-in-Class Treatment for Agitation in Alzheimer’s Disease Estimated 5.3M Americans have Alzheimer’s disease; approximately 50% of patients experience agitation – No currently approved therapies Phase 3 trials underway for blockbuster indication – Expected completion: Q3 20
Slide 15: 2016 Financial Results
2016 Financial Results 2016 Cash and Investments $ 96.2 M Revenue $ 174,000 Operating Expenses $ 51.3 M Shares outstanding 22.3 M 15 Following closing of the CTP-656 agreement with Vertex, cash is expected to fund the Company into 2021 – Based on $160 million upfront
Slide 16: 2017 Multiple Potential Value Creating Events
2017 Multiple Potential Value Creating Events 16 CTP-656 – Closing of asset purchase agreement with Vertex – Report US Phase 2 monotherapy top-line efficacy data (Q4 2017)* CTP-543 Report Phase 1 PD top-line data (Q1 2017) Report Phase 1 crossover data (Q1 2017) – Initiate Phase 2a trial (20
Slide 17: Proprietary and . All Rights Reserved. www.concertpharma.com For additional information contact: Justine Koenigsberg …
Proprietary and Confidential. © 2014 Concert Pharmaceuticals, Inc. All Rights Reserved. NASDAQ: CNCE www.concertpharma.com For additional information contact: Justine Koenigsberg ir@concertpharma.com
Concert Pharmaceuticals — Merger or Acquisition (April 2017) on 6ix